跳转至内容
Merck
CN

C1277

Sigma-Aldrich

氯硝西泮

powder

别名:

5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C15H10ClN3O3
化学文摘社编号:
1622-61-3
分子量:
315.71
EC 号:
216-596-2
MDL编号:
MFCD00057746
UNSPSC代码:
12352200
PubChem化学物质编号:
24892396
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

表单

powder

质量水平

200

药品控制

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

颜色

light yellow

创始人

Roche

SMILES字符串

Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

InChI key

DGBIGWXXNGSACT-UHFFFAOYSA-N

基因信息

human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)
rat ... Tspo(24230)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site.

特点和优势

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H336,H412

危险分类

Aquatic Chronic 3 - STOT SE 3

靶器官

Central nervous system

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000443604
0000443604
SLCP9841
SLCP1453
SLCH1836

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

W Löscher et al.
The Journal of pharmacology and experimental therapeutics, 279(2), 561-572 (1996-11-01)
We have reported recently that the seizure model and experimental protocol may markedly influence anticonvulsant tolerance and withdrawal characteristics of benzodiazepine (BDZ) receptor ligands so that predictions on tolerance and dependence liability of novel drugs should be based on a
John C Oakley et al.
The Journal of pharmacology and experimental therapeutics, 345(2), 215-224 (2013-02-21)
Seizures remain uncontrolled in 30% of patients with epilepsy, even with concurrent use of multiple drugs, and uncontrolled seizures result in increased morbidity and mortality. An extreme example is Dravet syndrome (DS), an infantile-onset severe epilepsy caused by heterozygous loss
Taeko Sasai et al.
Parkinsonism & related disorders, 19(2), 153-157 (2012-09-20)
The clinical effectiveness of pramipexole (PPX), a candidate treatment for idiopathic rapid eye movement sleep behavior disorder (iRBD), varies among individuals. This study investigates factors associated with PPX effectiveness for treating RBD symptoms. Ninety-eight consecutive patients with RBD who had
Laura González-Lafuente et al.
ACS chemical neuroscience, 3(7), 519-529 (2012-08-04)
Benzothiazepine CGP37157 is widely used as tool to explore the role of mitochondria in cell Ca(2+) handling, by its blocking effect of the mitochondria Na(+)/Ca(2+) exchanger. Recently, CGP37157 has shown to exhibit neuroprotective properties. In the trend to improve its
M L C Rodríguez et al.
Neuropharmacology, 64, 432-442 (2012-07-24)
A consolidated memory recalled by a specific reminder can become unstable (labile) and susceptible to facilitation or impairment for a discrete period of time. This labilization phase is followed by a process of stabilization called reconsolidation. The phenomenon has been
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持